Clinical Trials Logo

Clinical Trial Summary

Patients with acute leukemia derived from T lymphocytes have the characteristics of high expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to genetically modify the patient's T lymphocytes to target and eliminate tumor cells in a major histocompatibility complex-independent manner. CAR-T cells are costimulatory molecules that include single-chain antibodies (scFv) that recognize tumor-specific antigens, hinge regions, transmembrane regions, intracellular signaling regions (immunoreceptor tyrosine activation motif ITAM), and intracellular signaling regions. The chimeric antigen receptor of CD28 or CD137(4-1BB) conduction domain is expressed in a lentiviral vector, and the vector is transfected into autologous T cells, so that the modified CAR-T cells have targeting and specificity Recognizes and kills cancer cells expressing tumor antigens, and can proliferate and activate in vivo, but has no effect on cells that do not express the antigen


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04785833
Study type Interventional
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact xiaowen tang
Phone 13913538266
Email xwtang1020@163.com
Status Recruiting
Phase N/A
Start date March 4, 2021
Completion date February 4, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05398614 - SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies Phase 1
Active, not recruiting NCT04318678 - CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) Phase 1
Terminated NCT03422679 - Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Phase 1/Phase 2
Recruiting NCT06136364 - CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study Phase 1